What are the Rajabally criteria for diagnosing Guillain‑Barré syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Rajabally Criteria for GBS

The Rajabally criteria are electrodiagnostic criteria designed to classify Guillain-Barré syndrome subtypes (demyelinating vs. axonal) with improved diagnostic accuracy compared to older criteria sets, showing the highest sensitivity and specificity in pediatric populations when validated against reference standards 1, 2.

What Are the Rajabally Criteria?

The Rajabally criteria (published in 2015) represent an optimized electrodiagnostic classification system for GBS subtypes. These criteria were developed to improve upon earlier systems (Hadden, Ho, Dutch criteria) by:

  • Better identifying demyelinating features with sensitivity of 100% for demyelination 1
  • Accurately detecting axonal patterns with sensitivity of 97-100% for axonal subtypes 1
  • Reducing equivocal classifications with excellent agreement (0.93) when compared to Hadden criteria 1

Key Distinguishing Features

The Rajabally criteria incorporate several electrophysiological parameters to differentiate GBS subtypes:

  • Motor nerve conduction velocities and amplitude measurements
  • Temporal dispersion patterns in motor responses
  • Conduction block characteristics
  • Sensory nerve action potential abnormalities
  • Recognition of reversible conduction failure (RCF) as a feature that can occur in axonal GBS 2

Important Clinical Context

The Rajabally criteria showed superior diagnostic accuracy (misclassification error rate of 45%) compared to Hadden criteria (48%) when applied at first electrodiagnostic study 2. However, sparse linear discriminant analysis performed even better (15.3% error rate), suggesting room for further optimization 2.

Practical Application

When performing electrodiagnostic studies in suspected GBS:

  • Evaluate at least 4 motor nerves and 2 sensory nerves in both upper and lower limbs 1
  • Timing matters: Median duration from symptom onset to testing in validated studies was 7 days 1
  • Consider repeat studies: A second study 2-3 weeks later improves accuracy, particularly when initial findings show low amplitude responses or unclear demyelinating features 3

Critical Pitfall

Nearly half (46.6%) of axonal GBS patients show reversible conduction failure in motor nerves at second study 2. This means a single electrodiagnostic study may misclassify axonal cases as demyelinating, though this distinction does not currently alter treatment decisions 3, 4.

Limitations and Current Perspective

While the Rajabally criteria improve electrodiagnostic accuracy:

  • The demyelinating vs. axonal dichotomy is increasingly challenged and not endorsed by recent EAN/PNS guidelines 4
  • Treatment remains the same (IVIG or plasma exchange) regardless of electrophysiological subtype 4, 5
  • Electrodiagnostic studies are supportive but not required for GBS diagnosis, which remains primarily clinical 6

The Rajabally criteria are most useful for research purposes, prognostication, and understanding underlying pathophysiology rather than guiding acute treatment decisions 3.

References

Research

Optimizing the electrodiagnostic accuracy in Guillain-Barré syndrome subtypes: Criteria sets and sparse linear discriminant analysis.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2017

Research

The electrodiagnosis of Guillain-Barré syndrome subtypes: Where do we stand?

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2018

Research

Guillain-Barré syndrome: a comprehensive review.

European journal of neurology, 2024

Research

Guillain-Barré syndrome.

Nature reviews. Disease primers, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.